Myriad Genetics, Inc. (MYGN) return on equity (ROE)

Return on equity · fiscal 2025
-99.4%

Myriad Genetics, Inc. (MYGN) earned a return on equity of -99.4% in fiscal 2025 (the year ended December 31, 2025). That is 81.3 percentage points lower than the -18.2% of fiscal 2024. Figures as of 18 Nov 2026, 01:12 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on equity, fiscal 2025
-99.4%
Change on fiscal 2024
−81.3 pts
Highest on record
27.3%fiscal 2010
Lowest on record
-99.4%fiscal 2025
Fiscal years on record
182009–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Myriad Genetics, Inc. return on equity (ROE), in more detail

Across the 18 fiscal years on record (2009–2025), the highest was 27.3% in fiscal 2010 and the lowest -99.4% in fiscal 2025. The fiscal 2025 figure is no higher than in any of the 17 earlier fiscal years on record, whose median is 12.1%.

History · 18 fiscal years

Return on equity by fiscal year

Myriad Genetics, Inc. return on equity (ROE), year by year

Myriad Genetics, Inc. (MYGN) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
2025-99.4% 81.3 pts down
2024-18.2% 15.5 pts up
2023-33.6% 21.0 pts down
2022-12.6% 9.8 pts down
2021-2.8% 22.6 pts up
2020-25.4%—
2020-21.7% 22.1 pts down
20190.4% 13.4 pts down
201813.8% 11.5 pts up
20172.3% 13.6 pts down
201615.8% 3.8 pts up
201512.1% 12.4 pts down
201424.5% 4.3 pts up
201320.2% 2.6 pts up
201217.6% 0.1 pts down
201117.8% 9.5 pts down
201027.3% 7.8 pts up
200919.5%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

More on MYGN

Myriad Genetics, Inc., figure by figure

Myriad Genetics, Inc. (MYGN) overview: price, valuation and scorecard

Myriad Genetics, Inc. return on equity (ROE): questions and answers

What is Myriad Genetics, Inc.'s return on equity?

Myriad Genetics, Inc. (MYGN) earned a return on equity of -99.4% in fiscal 2025 (the year ended December 31, 2025). That is 81.3 percentage points lower than the -18.2% of fiscal 2024.

Is Myriad Genetics, Inc.'s return on equity high or low compared with its own history?

The fiscal 2025 figure is no higher than in any of the 17 earlier fiscal years on record, whose median is 12.1%.

What are the highest and lowest return on equity figures on record for Myriad Genetics, Inc.?

Across the 18 fiscal years on record (2009–2025), the highest was 27.3% in fiscal 2010 and the lowest -99.4% in fiscal 2025.

How is Myriad Genetics, Inc.'s return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Myriad Genetics, Inc. (MYGN) return on equity (ROE)”, data as of 18 November 2026. https://funkfolio.com/stock/MYGN/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.